Real-world effectiveness of omalizumab for severe allergic asthma treatment in Colombia

Carlos A. Torres-Duque1,2*, Jaime Ocampo-Gómez3, Mauricio Morales Castillo4, Diana Cano-Rosales5, Ángela Giraldo-Montoya6, Freddy Rodríguez7, Isabel Palacios-Ortega8, Mauricio Durán-Silva1, Humberto Reynales9, Elizabeth García3,10 and REXACOL Consortium1

Abstract

Background: The allergic phenotype is responsible for more than 50% of severe asthma cases. In a stepwise approach, add-on treatments such as anti-IgE are used for severe allergic asthma (SAA). This study was aimed to describe the real-world effectiveness of omalizumab in adult and pediatric patients with SAA in Colombia.

Methods: This was an observational, non-interventional, retrospective study. Data from patients with SAA that received at least one month of treatment with omalizumab was obtained from medical records at eight sites in Colombia. Time-zero (t−0) was defined as the date of initiation of omalizumab, and data was gathered for a 12-month period before t−0 and a 12-month period after t−0. Clinical outcomes, including exacerbations, were assessed at 6 and 12 months. Effectiveness of omalizumab was evaluated in terms of the reduction of the risk of exacerbations (annualized rate).

Results: We included 143 patients with SAA. There was a decrease of 72.4% of the annualized rate of clinically significant asthma exacerbations during the year after omalizumab (from 1.74 before to 0.48 after) with a substantial reduction of the risk of exacerbations by 56.7% (RR [95% CI] 0.43 [0.30–0.63], p < 0.001).

Conclusion: The use of omalizumab in Colombia as a treatment for SAA notably reduced the risk of clinically significant exacerbations. This study is the first to evaluate omalizumab real-life effectiveness in pediatric and adult patients in the country.

Keywords: Effectiveness, Exacerbations, Omalizumab, Severe allergic asthma, Real world

Background

Asthma is a frequent and potentially serious chronic disease that causes major negative impact on individual and public health [1, 2]. In Colombia, the asthma prevalence has been previously estimated at 9% in adults older than 40 years [3] and 12.1% in overall population [4].

Severe asthma (SA) is defined as that which requires high doses of inhaled corticosteroids combined with at least any other controller drug, usually a long-acting beta agonist, corresponding to step 5 of the Global Initiative for Asthma (GINA), or which requires systemic corticosteroids (SC) use for > 50% of the previous year to prevent it from becoming “uncontrolled” or which remains uncontrolled despite this therapy [5, 6]. SA counts for approximately 5% of the overall population of patients of asthma [7, 8]. It is estimated that the allergic sensitization (allergic phenotype) is responsible for at least 50% of the

*Correspondence: ctorres@neumologica.org
1 Present Address: Research Department, Fundación Neumológica Colombiana, Carrera 13 B No. 161 – 85, Bogotá, Colombia
Full list of author information is available at the end of the article
cases of SA, this allergic phenotype is known as severe allergic asthma [SAA] [9, 10].

The immunoglobulin E (IgE) is the central actor of the allergic pathophysiological pathway [11, 12], and omalizumab, an anti-IgE recombinant humanized monoclonal antibody that binds to circulating IgE, inhibits the allergic response in asthma. From the pivotal studies [13, 14], the cumulative evidence has demonstrated the efficacy of omalizumab in reducing the asthma exacerbations, hospitalizations, and steroid utilization, and in improving asthma symptom scores, physician reported global evaluation of treatment effectiveness (GETE), pulmonary function and quality of life in moderate to severe allergic asthma in adults and children [15–18], including an exploratory systematic review and meta-analysis in Latin America [19].

Several real-world studies have corroborated the benefits of omalizumab found in clinical trials [20–25]. In Colombia, a tropical country with cities located a low, medium, and high altitudes, the national food and drug authority (i.e., INVIMA) has approved omalizumab as an add on therapy for the treatment of adults and children (older than 6 years) affected with moderate or severe persistent allergic asthma, whose symptoms cannot be adequately controlled with high dose of inhaled corticosteroids [26, 27].

Although it has been described that allergies and allergic diseases could be different in the tropics [28], one report from our country showed that the prevalence of SAA in patients with SA was 62.1% [29] similar to that generally described. However, there is still little information about allergic asthma in tropical and developing countries. In addition, there is scarce published information about the clinical use of omalizumab in asthma in Colombia [30–32]. This study was aimed to evaluate the real-world effectiveness of omalizumab in this country.

Methods

Study design

This is an observational, non-interventional, multi-center, retrospective, real-world study aimed to evaluate the effectiveness of omalizumab in 143 patients diagnosed with SAA, who had received omalizumab in Colombia. We used secondary data obtained from medical records at participating sites. For this purpose, a before-and-after design was used defining time-zero (t-0) as initiation of add-on therapy with omalizumab. Data was gathered for a 12-month period before t − 0 and a 12-month period after t − 0. Clinical outcomes and asthma treatment were reassessed at 6 and 12 months after t − 0, which were defined as t − 1 and t − 2, respectively. In accordance with this design, the year prior to initiation of omalizumab was used as a non-intervened control group. In this study each patient represented his own control.

Study subjects, sample size and participant sites

We included patients over 6 years of age who had diagnosis of SAA, had received treatment for at least one month with omalizumab and had documented outcomes for a 24-month period (1 year before and one year after omalizumab). SA was defined according to current American Thoracic Society (ATS) and European Respiratory Society (ERS) (ATS/ERS) [5] and GINA [33] consensus and SAA as additionally having a total IgE > 30 IU/mL and positive prick test or specific IgE > 0.35 kU/L. In Colombia, patients do not have a unified electronic history. In a significant number of patients, the SPT and/or IgE results were not registered in the history of the research site, but the regulatory and the Social Security System requirement for prescription of omalizumab in the country is moderate to severe allergic asthma (SAA), non-controlled with high doses of inhaled corticosteroids, an IgE > 30 up to 1500 IU/mL and/or a positive SPT. So, patients with SAA diagnosis and prescribed with omalizumab, without a registered value of IgE or SPT, as a real-world study, were also accepted for the study. The participants attended medical evaluations and received the usual clinical management for their asthma.

An informed consent was signed at one participant site as requested by the institutional ethics committee (Fundación Neumológica Colombiana) and it was obtained by the site team in the first usual visit of the patients after the study approval. Informed consent was waived by the ethics committees at the other seven sites (please find the names of these ethics committees under the Declarations and Ethics approval and consent to participate section).

Exclusion criteria were defined as having other respiratory diseases different from asthma, polyposis or rhinitis, patients who had received any other biologic therapy for asthma or any investigational biologic therapy for asthma in the 24-month period or had received omalizumab as an off-label indication.

Considering previous analysis regarding real-world efficacy of omalizumab which reported reductions for asthma exacerbations and hospitalizations with Cohen’s d of 0.71 and 0.36, respectively, and selecting a size effect index > 0.25 and standard statistical thresholds of α = 0.05 and power = 0.8, a sample size of 143 subjects was calculated.

The study was carried out in eight sites from six cities in Colombia, as presented in Table 1. Data between 2013 and 2019 were collected for patients on treatment for SAA who met the selection criteria and for whom there was a 24-month period of medical history.
Clinical variables, measurements, and definitions

Data were obtained from the clinical records one year before and one year after the initiation of omalizumab. In addition to demographic data, we collected the following information: clinically significant exacerbations (defined as a worsening of asthma required a short cycle [three days or more] of oral corticosteroids [OCS] or, for patients who require regular long-term OCS administration, needed an increase in the OCS dose regimen [with or without hospital admission]); and/or hospitalization (a length of hospital stay of 24 h or more); and/or emergency room visit (any medical attention required by a respiratory cause, including asthma)), blood eosinophils count (EOS), serum IgE level, asthma control (any tool: asthma control questionnaire [ACQ], asthma control test [ACT], [GINA] assessment), spirometry variables (forced expiratory volume in one second \( [FEV_1] \), forced vital capacity \( [FVC] \) and \( FEV_1/FVC \) ratio), pharmacologic treatment for asthma (inhaled and systemic corticosteroids, beta-agonists treatment, adverse reactions to omalizumab, and any other drug used).

EOS measured in the year after to omalizumab initiation was described (eosinophilic phenotype was defined as an EOS \( \geq 300 \text{ cell}/\mu\text{L} \)). Allergic phenotype was defined by an IgE \( \geq 30 \text{ UI/mL} \) and a positive prick test (this phenotype also includes positive serum specific IgE test, but in Colombia access to this test is limited). Current ACT, ACQ and GINA control asthma tool was used and evaluated according to the accepted cutoff.

The change of the annualized rate of clinically significant exacerbations after starting omalizumab \( (t−1\text{ and }t−2) \) in comparison with the previous year \( (t−0) \) was defined as the primary endpoint. The description of baseline characteristics, emergency room visits, asthma-phenotype associated variables (EOS, prick test, serum total IgE and serum specific IgE), asthma-control variables (ACQ, ACT, GINA assessment), \( FEV_1 \), and adverse events occurrence were evaluated as secondary endpoints. The correlation between the EOS \( (<300 \text{ cells}/\mu\text{L or }>300 \text{ cells}/\mu\text{L}) \) and clinical outcomes (i.e., clinically significant exacerbations, hospitalizations, and emergency room visits) was assessed as exploratory endpoint. For a simple comparison between responder and non-responder to omalizumab patients, we used a reduction of at least 50% of the number of exacerbations after one year of the use of the biologic as criteria of responder.

Statistical analysis

Qualitative variables were expressed as absolute and relative frequencies, and quantitative variables as measurements of central tendency and dispersion, according to the Shapiro Wilk’s normality test. The annualized rate

**Table 1** Demographic and clinical characteristics at t0 (at starting omalizumab) \( (N=143) \)

| Characteristic                                      | All patients \((n:143)^a\) |
|----------------------------------------------------|-----------------------------|
| Age, median (IQR)                                  | 44 (24–57)                  |
| Sex, female, n (%)                                 | 96 (66.6)                   |
| Body Mass Index, median (IQR)                       | 25.52 (24.36–27.47)        |
| Type of health insurance affiliation, n (%)         |                             |
| Contributory                                       | 125 (87.4)                  |
| Special regimen                                    | 12 (8.4)                    |
| Subsidized                                         | 5 (3.5)                     |
| Other                                              | 1 (0.7)                     |
| Cities and sites, n (%)                            |                             |
| Bogotá, 2 sites                                    | 89 (62.2)                   |
| Bucaramanga, 1 site                                | 25 (17.5)                   |
| Pereira, 1 site                                    | 10 (7)                      |
| Medellin, 2 sites                                  | 10 (7)                      |
| Cali, 1 site                                       | 5 (3.5)                     |
| Barranquilla, 1 site                               | 4 (2.8)                     |
| Comorbidities, n (%)                               |                             |
| Rhinitis                                           | 91 (64.1)                   |
| Sinusitis                                          | 27 (18.9)                   |
| Nasal polyposis                                    | 24 (16.9)                   |
| Gastroesophageal reflux                            | 15 (10.6)                   |
| Other comorbidities                                | 90 (63.4)                   |
| Eosinophils blood count, n (%)                     |                             |
| < 300 cells/\(\mu\text{L}\)                        | 41 (51.9)                   |
| \(\geq 300 \text{ cells}/\mu\text{L}\)            | 38 (48.1)                   |
| IgE, serum levels, n (%)                           |                             |
| < 30 \text{ UI/mL}                                 | 2 (1.6)                     |
| \(\geq 30 \text{ UI/mL}\)                         | 118 (98.4)                  |
| Prick test result, n (%)                           |                             |
| Positive                                           | 71 (84.5)                   |
| Negative                                           | 13 (15.4)                   |
| Severe asthma classification criteria, n (%)       |                             |
| Steps 4 or 5 or use SC in more than 50% of the previous year | 116 (81.1)       |
| High doses of IC or SC to keep asthma under control | 27 (18.8)                 |
| GINA assessment for asthma control, n (%)          |                             |
| Uncontrolled                                       | 76 (76)                     |
| Partly controlled                                  | 16 (16)                     |
| Well controlled                                    | 8 (8)                       |
| Deworming 12 months before t−0, n (%)              |                             |
| Yes                                                | 8 (5.6)                     |
| No                                                 | 29 (20.3)                   |
| No data                                            | 106 (74.1)                  |

\(^a\) As it is explained in the text, not all the patients had a registered value of eosinophils, IgE and/or Prick test at starting omalizumab
of clinically significant exacerbations was calculated for each period. To evaluate effectiveness of omalizumab, we analyzed the change of the risk of exacerbations in terms of the reduction of the annualized rate of clinically significant exacerbations. Data from patients before omalizumab initiation time (t-0) were taken as control period (without exposure) and data after t-1 and t-2 were considered as intervention period (with exposure). To compare data between periods we used an analysis of variance (ANOVA) analysis. Data were analyzed for the whole group of participants and for the age groups <18 and ≥18 years old. To evaluate the effectiveness of omalizumab, a multivariate analysis approach for comparing multivariate sample means was done using a multivariate analysis of variance (MANOVA) technique and taking three times (12 months before (t-0), 6 and 12 months after starting omalizumab (t-1 and t-2)). The number of clinically significant exacerbations was adjusted according to age, gender, and GINA classification. We performed a logistic regression analysis using improvement of control (well and partial control) as dependent variable. For the bivariate and multivariate analysis, we used age, sex, rhinitis, nasal polyposis, gastroesophageal reflux, blood eosinophils count, IgE level, SPT and asthma severity as independent variables. Statistical significance was set at p < 0.05, the analysis was carried out with the statistical software Stata14®.

Results
A total of 143 patients with SAA were included in this study, with 113 (79%) of them being ≥18 years. Table 1 presents the demographic and clinical characteristics of the subjects; the median age was 44 years, 66.6% were female, and 64.1% had rhinitis as the most frequent comorbidity, followed by sinusitis (18.9%) and nasal polyposis (16.9%). Total EOS ≥ 300 cells/µL was observed in 48.1%, total IgE serum levels > 30 IU/mL in 98.4% and positive prick test in 85.5%.

The annualized rate of clinically significant asthma exacerbations was 1.74 in pre-omalizumab period and 0.48 in post-omalizumab period, with a reduction of 72.4% (Fig. 1). Omalizumab reduce the risk of exacerbations by 56.7% (RR [95% CI]: 0.43 [0.30–0.63] p < 0.001). The annualized rate of hospitalizations in pre-omalizumab period was 0.46 compared with 0.15 in post-omalizumab period, with a reduction of 67.4%. The annualized rate of emergency visits was 1.11 in pre-omalizumab period and 0.34 in post-omalizumab period, with a reduction of 69.4%.

Moreover, a significant decline of the number of exacerbations, hospitalizations and emergency visits was found at t-1 and t-2 both in patients <18 and ≥18 years old (p < 0.05 for all outcomes) (Fig. 2).

According to patient’s age and after starting omalizumab at t-1 and t-2, the incidence rate of clinically significant asthma exacerbations in patients ≥18 years old changed from 1.42 in the pre-omalizumab period to 0.37 at t-1 (73% reduction) and to 0.21 at t-2 with an additional reduction of 43%. The incidence rate of hospitalizations in pre-omalizumab period was 0.44, in period t-1 was 0.03 the reduction of the incidence rate of hospitalizations was 93% and persisted similar until t-2. The incidence rate of emergency visits was 0.97 in pre-omalizumab period, 0.26 at t-1 (73% reduction), and 0.17 at t-2 (34% additional reduction) (Fig. 1). A similar pattern of change was observed in subjects <18 years old, but with greater reductions at t-1 in this group (Fig. 2). The effect size on the reduction of exacerbations was higher in the pediatric population than the adult one (d Cohen: 1.01 [pediatric] vs. 0.33 [adults]).

Only 57% patients had availability of data concerning asthma control using GINA assessment criteria at t-0 or at least at one timepoint (t-1 and/or t-2) after starting omalizumab. The percentage of uncontrolled patients decreased considerably with 46% less patients being classified as uncontrolled at t-1 and remained similar until t-2. On the contrary, the percentage of patients classified as well controlled increased from 8% (t-0) to 44% (t-2). The change in the percentage of patients initially classified as partly controlled increased with almost 14% more patients at t-2. (Fig. 3). Not all patients were assessed consistently every 6 months; however, GINA criteria were retrospectively retrieved from medical records generated 12 months before Omalizumab use, at the time of initiation of Omalizumab and after 6 and 12 months. The number of patients whose medical records reported such data were 82, 100, 91 and 83 patients, for each moment in time respectively. Other tools of asthma control (ACT or ACQ) were significantly less used and hence this data was not reported.

Only 87 patients (60.8%) of the patients had the evaluation of the pre- and post-bronchodilator FEV₁ at t-0. Of these, 38 (43.7%) and 28 (32.2%) had a follow-up evaluation at t-1 and t-2 respectively. The proportion of patients with a pre-bronchodilator FEV₁ ≥ 80% significantly increased from 31.5% at t-0 to 43.5% and to 60.7% at t-1 and t-2, respectively (Fig. 4).

As per protocol inclusion criteria, at starting omalizumab (t-0) almost all patients (96.4%) used high or medium doses of ICS combined with a long-acting beta-agonist (LABA) and 11.5% used OCS. At t-0 some of these SAA patients also used a leukotriene modifier (80.5%) and/or a long-acting anticholinergic bronchodilator (LAMA) (32.5%). At t-2, only 3.5% of the patients who were receiving omalizumab continued using OCS, corresponding to a reduction of 69.5% of patients.
requiring OCS after one year. No other significant changes in the use of other medications for asthma was observed.

As exploratory objective, we found a trend towards a higher decrease in the number of clinically significant exacerbations at both t−1 and t−2 in patients with EOS ≥ 300 cells/µl. However, there was no statistically significant difference, possibly because of the small sample size (n = 143 patients). We did not find significant differences between responder and non-responder to omalizumab patients, although the responder subjects tended to be younger (p = 0.093). Similarly, we did not find any independent variable associated with improvement of asthma control in the multivariate analysis.

Discontinuation of omalizumab was documented in 23 (16%) patients from the study population, in 6 cases (4.2%) due to adverse events as depicted in Table 2.

**Discussion**

Our study consistently showed that in a real-world setting of patients with SAA older than 6 years in Colombia, add-on therapy with omalizumab was associated with a significant decrease of the annualized rate of clinically significant asthma exacerbations (72.4%) and a substantial reduction of the risk of exacerbations by 56.7% (RR [95% CI]: 0.43 [0.30–0.63], p < 0.001). Therapy with omalizumab was also associated with a significant reduction of hospitalizations and emergency room visits. Analyzed by age, these findings were similar in children and adolescents (< 18 years) and adults (≥ 18 years), although the effect size was higher in the pediatric population as it could be expected due to the greater relevance of allergy in this age group. Despite of the missing data, usual in real-world conditions, our study also showed a consistent improvement of asthma control and pulmonary function (FEV1), and a reduction of the proportion of patients requiring OCS.

This is the first study with a representative sample of children and adults confirming the benefits of omalizumab in patients with SAA in usual clinical practice conditions in Colombia. A previous real-life study in 61 children by Morales-Munera et al. [30] had shown similar results with a significant reduction of clinically relevant...
Fig. 3 Asthma control by GINA assessment. Each time of measurement shows the number of patients with available information (the total n = 143). The percentage of uncontrolled patients fell considerably after omalizumab treatment starting (t = 0) with approximately 46% less patients being classified as uncontrolled at t = 1. The percentage of well controlled patients increased from 8% to 44% at t = 2.

Fig. 4 Prebronchodilator FEV₁ assessment at starting omalizumab and follow-up. The percentage of patients with a prebronchodilator FEV₁ < 80% consistently decreased and, on the contrary, the percentage of patients with prebronchodilator FEV₁ ≥ 80% significantly increased after omalizumab initiation.
exacerbations and a decrease in controller drug consumption in 73% of patients.

The results of the current study showed superior outcomes in primary and secondary endpoints compared to other studies of similar characteristics published in both adult and children population [17, 20, 21, 23–25, 34]. We recognize that patients who are prescribed with omalizumab in our health system are closely monitored, which can improve the prescription and adherence to other pharmacological interventions and non-pharmacological measures. Although it is not possible to measure this effect in our study and it is possible that this influences the results, it is clear that the administration of omalizumab in patients with SAA in Colombia produces a benefit at least similar or greater than that described in randomized and real-life studies conducted with omalizumab.

Colombia is a tropical country with a high proportion of people living at medium and high altitudes. It is not clear what is the impact of these climate and geographic conditions on allergic sensitization and clinic expression of allergies [26], but some studies confirmed that the sensitization and allergic phenotype in asthma and severe asthma is at least as frequent (40–60%) in Colombia than that described in the literature [4, 27, 35]. Our study was not aimed to evaluate differences between the participant cities according to altitude or any other geographic, climate or environmental pollution variables.

Per protocol our patients were allergic, and they had high IgE and positive prick tests. The evaluation of EOS this population showed an almost equal distribution of eosinophilic and non-eosinophilic phenotypes which was an expected finding consistent with previously reported results [36]. Our exploratory analysis initially showed a trend towards a decrease in the mean number of clinically significant exacerbations for patients with high eosinophilic count (≥ 300 cells/µl), but it was not statistically significant due to the small subset of available data. Previous studies showed great improvement in all clinical outcomes with omalizumab regardless of EOS [22, 37, 38], which was also the case with our patients.

Our study also showed that the percentage of patients classified as uncontrolled decreased considerably with a parallel increase in the percentage of patients classified as partly controlled and well controlled. The positive impact of omalizumab on asthma control in our population is greater than that described in most of studies and similar to other studies [39, 40].

Our findings suggest a beneficial effect of omalizumab therapy on the FEV1. Unfortunately, we did not have enough data to trace the relevance of these findings. Some studies have reported modest benefits with greater improvements in lung function for adolescent patients after omalizumab use [41, 42].

We found a significant reduction of patients requiring OCS 12 months after omalizumab initiation. This finding has been observed in other studies with decreased corticosteroid requirements in all phenotypes after 6 months to one year of omalizumab treatment [41]. Our results suggest that complete or partial withdrawal of OCS could be considered after omalizumab initiation without compromising adequate asthma control, as supported by other studies which have reported complete discontinuation of OCS in almost 50% or more of patients after one year of omalizumab use [16, 22, 43]. The effects of long-term use of OCS for severe asthma management in adults have already been documented including acute and chronic conditions involving cardiovascular, metabolic, psychiatric and ocular diseases [24, 44]. Omalizumab may be introduced as a reasonable alternative for cases of severe allergic asthma to reduce side effects and a negative impact on quality of life.

There was not a significant reduction in the doses of the inhaled corticosteroids after 1 year of treatment with omalizumab. The participant centers are heterogeneous and usually there is not a structured plan for reduction of inhaled steroids after biologic initiation according to control improvement and exacerbations decrease. Because of the starting diagnosis was severe asthma in most of the patients and 55.4% persisted uncontrolled or partially controlled after 1 year, it is possible that treating physicians did not reduce the dose of inhaled corticosteroids in many of them and statistically significant reduction were not reached.

### Table 2 Causes of omalizumab discontinuation at t−1 and t−2

| Causes                                              | t−1 n (%) | t−2 n (%) |
|-----------------------------------------------------|-----------|-----------|
| Administrative barriers/health insurance company did not authorize | 3 (37.5)  | 1 (6.67)  |
| Adverse event                                      | 3 (37.5)  | 3 (20)    |
| Worsening of symptoms/therapy change                | 1 (12.5)  | –         |
| Suspended by pulmonologist decision (no explicit reason) | 1 (12.5)  | –         |
| Suspended by allergologist decision (no explicit reason) | –         | 3 (20)    |
| Distant home                                       | –         | 2 (13.3)  |
| Asthma exacerbation                                | –         | 1 (6.7)   |
| Diagnosis and treatment of cancer                   | –         | 1 (6.7)   |
| Weight gain                                        | –         | 1 (6.7)   |
| No response to treatment                           | –         | 1 (6.7)   |
| Persistence of shortness of breath and wheezing     | –         | 1 (6.7)   |
| Improvement and the need of provocation tests       | –         | 1 (6.7)   |
On the other hand, healthcare costs for patients with severe asthma may be three of four times higher than those with less complicated asthma. One study conducted in Brazil led to the conclusion that omalizumab add-on therapy could be cost-effective but nor directly, and could support the benefit of the long-term reduction in the number of exacerbations with omalizumab use [45]. Omalizumab’s clinical benefits and pharmacoeconomic features are maximized when patients are correctly selected for its use [31].

The main strength of our study is its real-life character and its representative sample which support the benefit of using of the intervention (omalizumab) in the clinical practice. In Colombia, omalizumab is available for most of the general population because its cost is covered by the National Health System. So, the starting and adherence to omalizumab are not influenced by the cost, and the subjects included in our study are representative of patients with severe allergic asthma using omalizumab in the country. We have important limitations related to the significant number of missing data and the variable quality of data acquisition which are recorded during the medical practice routine and depend on the attending physician or the medical history format (paper or electronic). Results from this study should be applied carefully to the general population in Colombia due to missing data for some of the executed analysis.

Conclusions
In a real-life setting in Colombia, the use of omalizumab as a treatment for severe allergic asthma significantly reduces the frequency of asthma exacerbations, hospitalizations and emergency room visits due to respiratory causes, and improves the asthma control in both adult and pediatric patients. Our results support that reduction or withdrawal of OCS could be considered after omalizumab initiation. This study revealed the effectiveness of omalizumab in patients with different phenotypic characteristics with a positive response to treatment. Future research is needed in Colombia to further explore a possible relationship between phenotypic characteristics of severe allergic asthma and cost-effectiveness of omalizumab for our healthcare system.

Acknowledgements
Catalina Sosa: Drafting the work and revising it critically; participation in final approval of the version to be published; ensuring that questions related to the accuracy or integrity of the work are appropriately investigated and resolved. Juan Pablo Manosalva: Drafting the work and revising it critically; participation in final approval of the version to be published; ensuring that questions related to the accuracy or integrity of the work are appropriately investigated and resolved. Carlos A. Torres-Duque, Juliana Proaños-Jurado, Diana Cano-Rosas, Alejandro Carreño, Ana M. Celis, Edgardo Chapman, Mauricio Durán-Silva, Elizabeth García, María B. García, Ángela Giraldo-Montoya, Mauricio González-García, Libardo Jiménez-Maldonado, Julían Londoño, Edison Morales, Unidad Alergológica, Medellín, Colombia, Mauricio Morales-Castillo, Jaime Ocampo-Gómez, Isabel Palacios-Ortega, Freddy Rodriguez, Viviana Valencia, Ingrid Vanegas, Leslie Vargas-Ramírez, Humberto Reynales.

Author contributions
CJT participated in conception and design of the work; patient recruitment, analysis, and interpretation of data for the work; drafting the work; participation in final approval of the version to be published. JGO participated in patient recruitment and acquisition of data from the medical records; participation in final approval of the version to be published. NM participated in conception and design of the work; participation in final approval of the version to be published. DCR participated in patient recruitment and acquisition of data from the medical records; participation in final approval of the version to be published. AGM participated in patient recruitment and acquisition of data from the medical records; participation in final approval of the version to be published. IRO participated in patient recruitment and acquisition of data from the medical records; participation in final approval of the version to be published. JRS participated in patient recruitment and acquisition of data from the medical records; participation in final approval of the version to be published. HR participated in patient recruitment and acquisition of data from the medical records; participation in final approval of the version to be published. EG participated in patient recruitment and acquisition of data from the medical records; analysis, and interpretation of data for the work; participation in final approval of the version to be published.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
This study (Protocol CIGE235BCO01 v3.0/October2019) was approved by the ethics committees of the coordinating center (Vita Ethics Committee, Chia, Colombia) as well as by the ethics committees of the participating centers in Colombia and their investigators (Centro Médico Imbanaco Ethics Committee, Fundación del Caribe para la Investigación Biomédica Ethics Committee, Fundación Neumológica Colombiana Ethics Committee, IPS Universitaria Ethics Committee, Instituto Neumológico del Oriente Ethics Committee) in accordance with the principles in the Declaration of Helsinki. Fundación Neumológica Ethics Committee requested an informed consent process to be performed with patients attending Fundación Neumológica Research Site, an informed consent form was designed an approved by this committee and applied with patients accordingly. All other participating sites obtained waivers to perform the informed consent process from their corresponding ethics committees, the list of ethics committees that provided waivers to...
apply an informed consent and the institution it was provided to are listed as follows: (1) Comité de Ética de Investigación del Centro Médico Imbanaco for Centro Médico Imbanaco. (2) Comité de Ética en la Investigación CAIMED for Centro de Atención e Investigación Médica CAIMED. (3) Comité de Ética en Investigación Biomedica del Instituto Neumológico del Oriente (CEINO). (4) Comité de Ética e Investigación IPS Universitaria for IPS Universitaria. (5) Comité de Ética e Investigación IPS Universitaria for Unidad Alergológica. (6) Comité de Ética en la Investigación CAIMED for Unidad Médico Quirúrgica de O RL S.A.S. (7) Comité de Ética en la Investigación CAIMED for Ángela María Giraldo Montoya as Principal Investigator. (8) Comité de Ética en la Investigación CAIMED for Elizabeth García as Principal Investigator.

Consent for publication
Not applicable.

Competing interests
EG received funding from Novartis for the publication of this manuscript. JOG received funding from Novartis for the publication of this manuscript and has participated as speaker for the same company. RM currently works for Novartis de Colombia S.A. HR currently works as the executive director for CAIMED Chia.

Author details
1 Present Address: Research Department, Fundación Neumológica Colombiana, Carrera 13 B No. 161 – 85, Bogotá, Colombia. 2 Universidad de La Sabana, Chía, Colombia. 3 Unidad Médico Quirúrgica O RL – UNIMED, Bogotá, Colombia. 4 Novartis de Colombia SA, Bogotá, Colombia. 5 Instituto Neumológico del Oriente, Bucaramanga, Colombia. 6 Universidad Tecnológica de Pereira, Pereira, Colombia. 7 IPS Universitaria, Medellín, Colombia. 8 Centro Médico Imbanaco, Cali, Colombia. 9 Centro de Atención e Investigación Médica – CAIMED, Chía, Colombia. 10 Universidad de Los Andes, Bogotá, Colombia. 11 Centro Unidad de Alergología, Barranquilla, Colombia. 12 Unidad Alergológica, Medellín, Colombia.

Received: 6 April 2022 Accepted: 16 November 2022
Published online: 28 November 2022

References
1. Global Asthma Network. The Global Asthma Report 2018. Auckland, New Zealand: Global Asthma Network, 2018.
2. Asher MI, García-Marcos L, Pearce NE, Strachan DP. Trends in worldwide asthma prevalence. Eur Respir J. 2020;56:2002094.
3. Gonzalez-García M, Caballero A, Jaramillo C, Maldonado D, Torres-Duque AA. Prevalence, risk factors and underdiagnosis of asthma and wheezing in adults 40 years and older: a population-based study. J Asthma. 2015;52:823–30.
4. Dennis RJ, Caraballo L, García E, Rojas MX, Rondon MA, Pérez A, Aristizabal G, Peñaranda A, Barragan AM, Ahumada V, Jimenez S. Prevalence of asthma and other allergic conditions in Colombia 2009–2010: a cross-sectional study. BMC Pulm Med. 2012;12:17.
5. Chung KF, Wenzel SE, Bouzek JL, Bush A, Castro M, Sterk PJ, Adcock IM, Bateman ED, Bel EH, Bleecker ER, Boulet LP, Brightling C, Chanzon P, Dahlén SE, Djukanovic R, Frey U, Gama M, Gibson P, Hamid Q, Jobanputra P, Mauad T, Sorkness RL, Teague WG. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma: a systematic review and meta-analysis. Scien Rep. 2015;5:8191.
6. Normansell R, Walker S, Milan SJ, Walters EH, Nair P. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014;2014:CD005559.
7. Corren J, Kavati A, Ortiz B, Colby JA, Ruiz K, Maiese BA, Cadarette SM, Hanania NA, Boulet L-P. Global Initiative for Asthma (GINA) strategy 2021—executive summary and rationale for key changes. Am J Respir Crit Care Med. 2021;204:1387–208.
8. Hekking PW, Wener RR, Amelink M, Zwinderman AH, Bouvy ML, Bel EH. The prevalence of severe refractory asthma. J Allergy Clin Immunol. 2015;135:896–902.
9. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. Eur Respir J. 2003;22:470–7.
10. Paikasela J, Ilmarinen P, Honkamaa J, Tuomisto LE, Andersson H, Piipila P, Hisinger-Mölkänen H, Sovijäri A, Backman H, Lundback B, Rönmark E, Kankaanranta H, Lehtimäki L. Age-specific incidence of allergic and non-allergic asthma. BMC Pulm Med. 2020;20:9.
11. Ovchinnikov CE. Immunoglobulin E role in asthma and allergic disease: lessons from the clinic. Pharmacol Ther. 2007;113:121–33.
12. Frodure A, Mouthuy J, Durham SR, Chanze P, Bibille Y, Pilette C. Asthma phenotypes and IgE responses. Eur Respir J. 2016;47:304–19.
13. Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J, Beeh KM, Ramos S, Canonica GW, Hedgecock S, Fox H, Blobb M, Surrey K. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment). INNOVATE. Allergy. 2005;60:309–16.
14. Novak D. Management of asthma with anti-immunoglobulin E: a review of clinical trials of omalizumab. Respir Med. 2006;100:1907–17.
15. Lai T, Wang S, Xu Z, Zhang C, Zhao Y, Hu Y, Cao Y, Ying S, Chen Z, Li W, Wu B, Shen H. Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis. Sci Rep. 2015;5:8191.
16. Novartis de Colombia S.A. Declaración Sucinta Xolair, Referencia NSS v 4.2021.
17. Miranda P. The effectiveness of omalizumab in the control of severe uncontrolled asthma in Latin America—an exploratory systematic review and meta-analysis. Rev Alerg Mex. 2020;67:19–24.
18. Lee JK, Amin S, Erdmann M, Kukaswadia A, Ivanovic J, Fischer A, Gerendon A. Real-world observational study on the characteristics and treatment patterns of allergic asthma patients receiving omalizumab in Canada. Patient Prefer Adherence. 2020;14:725–35.
19. Bousquet J, Humbert M, Gibson PG, Costikas K, Jaumont X, Pfister P, Nissen F. Real-world effectiveness of omalizumab in severe allergic asthma: a meta-analysis of observational studies. J Allergy Clin Immunol Pract. 2019;7:2702–14.
20. Humbert M, Taille C, Maia L, Le Gros V, Just M, Molmard M. Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study. Eur Respir J. 2018;51:702523.
21. Canonica GW, Rottoli P, Bucca C, Zappa MC, Michetti G, Macciocchi B, Caruso C, Santus P, Bartezagh M, Rigoni L. Improvement of patient-reported outcomes in severe allergic asthma by omalizumab treatment: the real life observational PROXIMA study. World Allergy Organ J. 2018;11:33.
22. Bhutani M, Yang WH, Hébert J, de Takacsy F, Stril JL. The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma. The ASTERIX Observational study. PLoS ONE. 2017;12:e0183869.
23. Abraham I, Alhossain A, Lee CS, Kutbi H, MacDonald K. “Real-life” effectiveness studies of omalizumab in adult patients with severe persistent allergic asthma: systematic review. Allergy. 2016;71:593–610.
24. Novartis de Colombia S.A. FICHA TÉCNICA DE PRODUCTO FRM 7062237 V 1.0.
25. Novartis de Colombia S.A. Declaración Sucinta Xolair, Referencia NSS v 3.0. December 4, 2018.
26. Caraballo L, Zakzuk J, Lee BW, Acevedo N, Soh JY, Sánchez-Borges M, Hossny E, García E, Rosario N, Anstotegui I, Puerta L, Sánchez J, Cardona V. Particularities of allergy in the tropics. World Allergy Organ J. 2016;9:20.
29. Torres-Duque C, Ali-Munive A, Durán M, Aguirre C, Pareja M, González-García M. Asma grave en una ciudad tropical a gran altura. Respirar. 2019;11:56.
30. Morales-Múnera O, Pedraza Á. Niño-Serna L. Omalizumab in children with uncontrolled asthma: a real-life study carried out in Colombia. Rev Alerg Mex. 2018;65:222–32.
31. Rodríguez-Martínez CE, Sossa-Briceno MP, Castro-Rodriguez JA. Cost-utility of omalizumab for the treatment of uncontrolled moderate-to-severe persistent pediatric allergic asthma in a middle-income country. Pediatr Pulmonol. 2021;56:2987–96.
32. Buendia JA, Guerrero Patiño D, Cosso-Giraldo YE. Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma. J Asthma. 2021;59:1–8.
33. Reddel HK, Bateman ED, Becker A, Boulet LP, Cruz AA, Drazen JM, Haahntela T, Hurd SS, Inoue H, de Jongste JC, Lemanske RF Jr, Levy ML, O’Byrne PM, Paggiaro P, Pedersen SE, Pizzichini E, Soto-Quiróz M, Szeffler SJ, Wong GW, FitzGerald JM. A summary of the new GINA strategy: a roadmap to asthma control. Eur Respir J. 2015;46:622–39.
34. Chippis BE, Lanier B, Milgrom H, Deschlidire A, Hedlin G, Szeffler SJ, Kattan M, Kianifard F, Ortiz B, Haselkorn T, Iqbal A, Rosén K, Trzaskoma B, Busse WW. Omalizumab in children with uncontrolled allergic asthma: review of clinical trial and real-world experience. J Allergy Clin Immunol. 2017;139:1431–44.
35. Duenas-Meza E, Torres-Duque CA, Correa-Vera E, Suárez M, Vásquez C, Jurado D, Del Socorro MM, Barón O, Pareja-Zabala MJ, Giraldo-Cadavid LF. High prevalence of house dust mite sensitization in children with severe asthma living at high altitude in a tropical country. Pediatr Pulmonol. 2018;53:1356–61.
36. Fitzpatrick AM, Moore WC. Severe asthma phenotypes: How should they guide evaluation and treatment? J Allergy Clin Immunol Pract. 2017;5:901–8.
37. Matucci A, Vultaggio A, Maggi E, Kasujej I. Is IgE or eosinophils the key player in allergic asthma pathogenesis? Are we asking the right question? Respir Res. 2018;19:113.
38. Carr TF, Zeki AA, Kraft M. Eosinophilic and noneosinophilic asthma. Am J Respir Crit Care Med. 2018;197:22–37.
39. Kirchnerová OR, Valena T, Novosad J, Ťerl M. Real-world effectiveness and safety of omalizumab in patients with uncontrolled severe allergic asthma from the Czech Republic. Postepy Dermatol Alergol. 2019;36:34–43.
40. Novelli F, Latorre M, Vergura L, Caialfia MF, Camiciottoli G, Guarnieri G, Matucci A, Macchia L, Vianello A, Vultaggio A, Celi A, Cazzola M, Paggiaro P. Asthma control in severe asthmatics under treatment with omalizumab: a cross-sectional observational study in Italy. Pulm Pharmacol Ther. 2015;31:123–9.
41. Campo P, Soto Campos G, Aparicio MB, Jorge AM, González Expósito HM, Quirce S, Dávila I. Severe asthma phenotypes in patients controlled with omalizumab: a real-world study. Respir Med. 2019;159:105804.
42. Casale TB, Luskin AT, Busse W, Zeiger RS, Trzaskoma B, Yang M, Griffin NM, Chippis BE. Omalizumab effectiveness by biomarker status in patients with asthma: evidence from PROSPERO, a prospective real-world study. J Allergy Clin Immunol Pract. 2019;7:156-164.e151.
43. Rodrigo GJ, Neffen H, Castro-Rodriguez JA. Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest. 2011;139:28–35.
44. Volmer T, Effenberger T, Trautner C, Buhl R. Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature. Eur Respir J. 2018;52:1800703.
45. Suzuki C, Lopes da Silva N, Kumar P, Pathak R, Ong SH. Cost-effectiveness of omalizumab add-on to standard-of-care therapy in patients with uncontrolled severe allergic asthma in a Brazilian healthcare setting. J Med Econ. 2017;20:832–9.